Perez-Santos Martin (Martin Perez-Santos)

ResearcherID Scopus Author ID ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 24

Top Venues

Pharmaceutical patent analyst

Expert opinion on therapeutic patents

Expert opinion on drug discovery

Benemérita Universidad Autónoma de Puebla

Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (PHD)

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Benemérita Universidad Autónoma de Puebla Sep 01 2011

Mexico

Coordinador :: Oficina de Transferencia de Tecnología

Instituto Mexicano de la Propiedad Industrial Nov 01 2000 - Dec 31 2012

Mexico

Coordinator

Education History

Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional Jul 01 1997 - Nov 15 2001

Mexico

PHD :: Patología Experimental

Publications

Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Perez-Santos Martin
Patenting trends by Mexican pharmaceutical companies. Pharmaceutical patent analyst 12 (6) (2024)
Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Perez-Santos Martin
Patenting trends by Mexican pharmaceutical companies. Pharmaceutical patent analyst 12 (6) (2024)
Luis Villafaña-Diaz, Juan C Perez-Garcia, Diana Barron-Villaverde, Perez-Santos Martin
Patenting trends by Mexican pharmaceutical companies. Pharmaceutical patent analyst (2024)
Nemesio Villa-Ruano, Vianey Marin-Cevada, Gabriela Sánchez Esgua, Luis Villafaña-Diaz, Perez-Santos Martin
Drug repurposing of rimantadine for treatment of cancer. Pharmaceutical patent analyst (2023)
Gabriela Sánchez Esgua, Juan Reyes-Alvarez, Perez-Santos Martin
Patenting trends in the pharmaceutical field of Mexican universities . Pharmaceutical patent analyst (2023)
Nemesio Villa-Ruano, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Diana Barron-Villaverde, Perez-Santos Martin
Drug repurposing of Mito-Atovaquone for cancer treatment. Pharmaceutical patent analyst (2023)
Maricruz Anaya-Ruiz, Perez-Santos Martin
Drug repurposing of adapalene for melanoma treatment. Pharmaceutical patent analyst 11 (1) (2022)
Viridiana I Flores-Quiroz, Lino Zumaquero-Ríos, Perez-Santos Martin
Pharmaceutical agents for the treatment of Chagas disease: patenting trends in the 2016-2021 period. Pharmaceutical patent analyst 11 (3) (2022)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Luis Villafaña-Diaz, Gabriela Sánchez Esgua
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents. Expert opinion on drug discovery (2022)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Gabriela Sánchez Esgua, Luis Villafaña-Diaz, Diana Barron-Villaverde
Treatment of solid tumors using bispecific anti-PDL-1/ICOS antibody. Pharmaceutical patent analyst 10 (2) (2021)
Perez-Santos Martin
Bispecific anti-OX40/5T4 antibodies for cancer treatment. Pharmaceutical patent analyst 10 (2) (2021)
Maricruz Anaya-Ruiz, Perez-Santos Martin
Small-molecule inhibitor PD-1/PD-L1 interaction for colorectal cancer treatment. Pharmaceutical patent analyst (2021)
Lourdes Millán-Pérez Peña, Perez-Santos Martin, Irma Herrera-Camacho, Bandala Cindy, Maricruz Anaya-Ruiz
Colon carcinoma treatment using bispecific anti-GITR/CTLA-4 antibodies: a patent evaluation of WO2018091739. Expert opinion on therapeutic patents 30 (5) (2020)
Jorge Cebada, Perez-Santos Martin, Bandala Cindy, Eleazar Lara-Padilla, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Perez Peña, Eduardo Monjaraz, Amira Flores, Maricruz Anaya-Ruiz
OX40 agonists for cancer treatment: a patent review. Expert opinion on therapeutic patents 31 (1) (2020)
Perez-Santos Martin
Bispecific anti-PD-1/CTLA-4 antibody for advanced solid tumors. Pharmaceutical patent analyst 9 (5) (2020)
Nemesio Villa-Ruano, Tayde Guerrero-González, Eduardo Gómez-Conde, Perez-Santos Martin
Bispecific anti-PD-L1/PD-1 antibodies for advanced solid tumors: a patent evaluation of US2019010232. Expert opinion on therapeutic patents 30 (10) (2020)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Nora Hilda Rosas-Murrieta, Lourdes Millán-Pérez Peña
Cancer combinatorial immunotherapy using etigilimab and nivolumab: a patent evaluation of WO2018102536. Expert opinion on therapeutic patents 30 (2) (2020)
Perez-Santos Martin, Tayde Guerrero-González, Eduardo Gómez-Conde, Jorge Cebada, Amira Flores, Nemesio Villa-Ruano
Treatment of cancer with an anti-KIR antibody: a patent evaluation of US9879082 and US2018208652. Expert opinion on therapeutic patents 30 (3) (2020)
Jorge Cebada, Amira Flores, Bandala Cindy, Ian Lizaliturri-Flores, Nemesio Villa-Ruano, Perez-Santos Martin
Bispecific anti-PD-1/LAG-3 antibodies for treatment of advanced or metastatic solid tumors: a patent evaluation of US2018326054. Expert opinion on therapeutic patents 30 (7) (2020)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Lourdes Millán-Pérez Peña, Nora Hilda Rosas-Murrieta
Bispecific anti-OX40/CTLA-4 antibodies for advanced solid tumors: a patent evaluation of WO2018202649. Expert opinion on therapeutic patents 29 (12) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Jorge Cebada, Bandala Cindy, Gerardo Landeta, Patricia Martínez-Morales, Nemesio Villa-Ruano
LAG-3 antagonists by cancer treatment: a patent review. Expert opinion on therapeutic patents 29 (8) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Irma Herrera-Camacho, Lourdes Millán-Pérez Peña
Cancer combinatorial immunotherapy using anti-OX40 agonist and anti-PD-L1 antagonist: a patent evaluation of US2018256711A1. Expert opinion on therapeutic patents 29 (7) (2019)
Irma Herrera-Camacho, Maricruz Anaya-Ruiz, Perez-Santos Martin, Lourdes Millán-Pérez Peña, Bandala Cindy, Gerardo Landeta
Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1. Expert opinion on therapeutic patents 29 (8) (2019)
Perez-Santos Martin, Maricruz Anaya-Ruiz, Jorge Cebada, Irma Herrera-Camacho
Treatment of cancer with a combination of LAG-3Ig and anti-PD-1/anti-PD-L1 antibodies: a patent evaluation of US2018271940 A1. Expert opinion on therapeutic patents 29 (5) (2019)

Perez-Santos Martin.css-eqlu8i{font-size:small;padding-left:4px;} (Martin Perez-Santos)

Publication Activity (10 Years)

Top Topics

Top Venues

Perez-Santos Martin (Martin Perez-Santos)